A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
NCT ID: NCT05991674
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2023-06-30
2023-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Allergy Skin Patch Artificial Intelligence (AI)
NCT05339750
Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy
NCT01953380
Characterization of Chronic Hand Eczema
NCT05026554
Immune Reactions in Contact Dermatitis Affected Skin
NCT01546298
Natural History of Severe Allergic Inflammation and Reactions
NCT01164241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allergic Contact Dermatitis Patients
patch test for diagnosing allergic contact dermatitis
European Baseline Series (EBS) System of allergens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
patch test for diagnosing allergic contact dermatitis
European Baseline Series (EBS) System of allergens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Eligible patients were adults diagnosed with dermatitis who had a positive patch test result on the chemical panel of Baseline Series of Allergens.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Andreas Syggros Hospital of Venereal and Dermatological Diseases
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GEORGIA KOKLA
Chief Administrative Secretary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Georgia Gogkla
Athens, Attica, Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
131/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.